share_log

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

Benzinga ·  May 9 07:56

HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment